Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study

CNS Spectrums
Michael E ThaseRod J Hughes

Abstract

Many patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitors have residual symptoms (eg, persistent fatigue, excessive sleepiness) despite an overall antidepressant response. Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms. This 12-week, open-label, dose titration, extension study followed an 8-week placebo-controlled study of modafinil augmentation in patients with MDD. The dose was 100-400 mg/day. The median stable dose was 300 mg/day. Assessments were the Epworth Sleepiness Scale, Brief Fatigue Inventory, Clinical Global Impression of Improvement scale, 17-item Hamilton Rating Scale for Depression, and Montgomery-Asberg Depression Rating Scale. Of the 245 patients treated, 194 completed the study; 70% reported Clinical Global Impression of Improvement scale responses of "much improved" or "very much improved" between open-label baseline and final visit (previous randomized modafinil group: 74%; placebo group: 66%). When data were analyzed for four subsets of patients (former modafinil responders, placebo responders, modafinil nonresponders, and placebo nonresponders), improvements in scores on all outcome measures were at lea...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Jan 15, 1995·Biological Psychiatry·A L Sharpley, P J Cowen
Oct 1, 1996·Thyroid : Official Journal of the American Thyroid Association·A J Prange
Dec 24, 1998·Journal of Clinical Psychopharmacology·E C Dimitriou, C E Dimitriou
Apr 30, 1999·The Journal of Clinical Psychiatry·A A NierenbergM Fava
May 18, 2000·Clinical Therapeutics·L B Marangell
Jun 10, 2000·The Journal of Clinical Psychiatry·M A MenzaA Castellanos
May 10, 2001·The International Journal of Neuropsychopharmacology·Andreas Baumgartner
Jun 20, 2002·Psychopharmacology·V Deroche-GamonetP V Piazza
Nov 28, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Giovanni Andrea FavaNicoletta Sonino
Feb 18, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·M Bauer, P C Whybrow
Mar 18, 2003·Journal of Clinical Psychopharmacology·Paul J Markovitz, Susan Wagner
Aug 9, 2003·European Archives of Psychiatry and Clinical Neuroscience·Michael BauerTom Bschor
Jan 8, 2004·Journal of Clinical Psychopharmacology·Charles DeBattistaJennifer Poirier
Mar 9, 2004·The Journal of Clinical Psychiatry·George I PapakostasMaurizio Fava
Aug 27, 2004·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Hugh MyrickSteven LaRowe
Sep 16, 2004·The Journal of Clinical Psychiatry·Thomas L SchwartzNicole Jones

❮ Previous
Next ❯

Citations

Jun 24, 2006·CNS Spectrums·Jerald Block
Feb 1, 2007·The Annals of Pharmacotherapy·Prasad R PadalaSubhash C Bhatia
Nov 5, 2008·Current Psychiatry Reports·Richard C Shelton, Rakesh Reddy
Dec 17, 2008·Digestive Diseases and Sciences·S Ian GanMarshall M Kaplan
Jan 6, 2009·Current Opinion in Psychiatry·André F CarvalhoJoão L Cavalcante
Dec 5, 2009·CNS Drugs·Chi-Un PaeAshwin A Patkar
Jan 22, 2010·CNS Drugs·Richard C SheltonSara A Corya
Mar 5, 2014·European Archives of Psychiatry and Clinical Neuroscience·Florian SeemüllerHans-Jürgen Möller
Jul 12, 2014·Annual Review of Biomedical Engineering·Deanna M ThompsonChristine E Schmidt
Feb 3, 2007·Alimentary Pharmacology & Therapeutics·D E J Jones, J L Newton
Sep 19, 2007·Journal of Clinical Pharmacy and Therapeutics·A F CarvalhoM C O Lima
Mar 20, 2010·CNS Drugs·Tracy L GreerMadhukar H Trivedi
Jul 15, 2009·Acta Psychiatrica Scandinavica·G Parker, H Brotchie
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael J Minzenberg, Cameron S Carter
Jul 20, 2016·Neuroscience Bulletin·Philippe Leff-GelmanDavid Ellioth Pulido-Ascencio
Jun 12, 2008·International Clinical Psychopharmacology·Alfredo Carlo AltamuraEmanuela Mundo
Aug 31, 2012·European Archives of Psychiatry and Clinical Neuroscience·Claus NormannLukas Frase
May 7, 2021·The Psychiatric Quarterly·Sevlin BozMatthieu Hein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.